MiPLA

MiPLA (N-methyl-N-isopropyl lysergamide, also known as lysergic acid methylisopropylamide) is a synthetic psychedelic of the lysergamide family. It is structurally distinct from LSD in its amide substitution: where LSD carries a symmetric diethyl amide group, MiPLA features an asymmetric N-methyl-N-isopropyl amide — one methyl group and one isopropyl group on the amide nitrogen. This structural difference modifies the steric and electronic properties of the amide binding pocket interaction with 5-HT2A receptors. MiPLA acts as a direct compound in its own right and is the parent molecule for the prodrug 1cP-MiPLA.

Community experience with MiPLA describes a psychedelic experience that is notably shorter than LSD, typically 4–7 hours, with a character that users frequently describe as more mentally clear and less visually overwhelming than LSD. Some users describe the experience as having a more manageable quality — retaining cognitive clarity at doses that would be intensely overwhelming with LSD. This has made MiPLA of particular interest to users who value a shorter, cleaner lysergamide experience. Community reports from those microdosing note subtle but real effects at sub-perceptual doses, described as improving mood and focus.

MiPLA occupies a relatively obscure position in the broader lysergamide landscape, overshadowed by more widely documented compounds such as 1P-LSD and AL-LAD. However, its genuinely distinct character compared to LSD — rather than simply being an LSD equivalent — has attracted dedicated community interest among those exploring lysergamide diversity. The shorter duration and reportedly cleaner headspace make it relevant for specific use cases.

Testing with Ehrlich reagent is essential before use. Do not confuse with MiPT (N-methyl-N-isopropyl tryptamine), a tryptamine compound — despite name similarity, these are pharmacologically unrelated.